Working… Menu

Hormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01569945
Recruitment Status : Completed
First Posted : April 3, 2012
Last Update Posted : September 10, 2014
Information provided by (Responsible Party):
Thomas D'Hooghe, University Hospital, Gasthuisberg

Brief Summary:
What is the best medication for hormonal stimulation in cycles with high intra-uterine insemination: tablets of Clomifen (5 days) followed by tablets of Ethinyl Estradiol (5 days) or daily injections with Human Menopausal Gonadotropin (Menopur)?

Condition or disease Intervention/treatment Phase
Subfertility Drug: Clomifen, Ethinyl Estradiol Drug: Menotropins Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 371 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : September 2004
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2011

Arm Intervention/treatment
Active Comparator: Tablets
Clomifen (5 days) followed by Ethinyl Estradiol (5 days)
Drug: Clomifen, Ethinyl Estradiol
starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected

Active Comparator: human menopausal gonadotropins
Daily Injections
Drug: Menotropins
Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU

Primary Outcome Measures :
  1. pregnancy rate [ Time Frame: on average 30 days if not pregnant and 12 weeks if pregnant ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • women younger than 42 years old
  • infertility of at least one year
  • normal tubal, pelvic and uterine anatomy
  • semen with total motility count of at least 5 million (at least one sample)

Exclusion Criteria:

  • premature ovarian failure
  • medical history of tubal or ovarian surgery
  • tubal or pelvic adhesions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01569945

Layout table for location information
Leuven University Fertility Center
Leuven, Vlaams Brabant, Belgium, 3000
Sponsors and Collaborators
University Hospital, Gasthuisberg
Layout table for investigator information
Principal Investigator: Thomas D'Hooghe, MD PhD University Hospital, Gasthuisberg
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Thomas D'Hooghe, Profsessor Medical Doctor, University Hospital, Gasthuisberg Identifier: NCT01569945    
Other Study ID Numbers: ML2436 - 1
First Posted: April 3, 2012    Key Record Dates
Last Update Posted: September 10, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Ethinyl Estradiol
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Reproductive Control Agents
Estrogen Antagonists
Hormone Antagonists
Fertility Agents, Female
Fertility Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators